NYSE · Drug Manufacturers - General

Zoetis Inc. (ZTS) Stock

$73.08 +2.14% NYSE: ZTS Healthcare

Valuation

MetricValue
Price$73.08
Market Cap$30.64B
P/E Ratio11.69
P/B Ratio9.43
P/S Ratio3.13
EPS (TTM)$6.02
52-Week High$148.79
52-Week Low$69.03
Dividend Yield2.98%

Financials & Margins

MetricValue
ROE69.25%
ROA17.35%
ROCE27.05%
Gross Margin38.00%
Operating Margin38.00%
Net Margin27.49%
Debt/Equity2.93
Current Ratio3.03

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.8B$8.1B$8.5B$9.3B$9.5B
Operating Profit$2.8B$2.9B$3.1B$3.4B$3.6B
Net Profit$2.0B$2.1B$2.3B$2.5B$2.7B
EPS$4.27$4.49$5.07$5.47$6.02
Op Margin36.0%36.2%35.9%36.6%38.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.9B$14.9B$14.3B$14.2B$15.5B
Total Liabilities$9.4B$10.5B$9.3B$9.5B$12.1B
Cash$3.5B$3.6B$2.0B$2.0B$2.3B
Borrowings$6.7B$8.1B$6.8B$6.7B$9.5B

Latest News

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union Business Wire · Jul 15, 2026 Zoetis (ZTS) Stock Dips While Market Gains: Key Facts Zacks · Jul 14, 2026 Zoetis to Acquire Veterinary Teleradiology Services Platform VitalRADS MT Newswires · Jul 14, 2026 Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities Business Wire · Jul 14, 2026 Leerink Partners Adjusts Zoetis Price Target to $80 From $95, Maintains Market Perform Rating MT Newswires · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.2B$1.9B$2.4B$3.0B$2.9B
Investing Cash Flow$-935.0M$-1.5B$-1.5B$-970.0M$-1.4B
Financing Cash Flow$-788.0M$-1.6B$-1.1B$-1.9B$-3.2B
Net Cash Flow$-119.0M$96.0M$-1.5B$-54.0M$325.0M
Free Cash Flow$1.7B$1.3B$1.6B$2.3B$2.3B

Valuation & Return Ratios

MetricValue
PEG Ratio2.62
EV / EBITDA9.69
FCF Yield7.94%
Quick Ratio1.84
Interest Coverage14.43
Return 1Y-49.77%
Return 3Y-57.49%
Return 5Y-61.92%

Ownership

Insiders Held0.15%
Institutions Held102.86%
Institutions Float Held103.02%
Institutional HolderSharesReport Date
Blackrock Inc.35,584,3122026-03-31
Vanguard Capital Management LLC26,072,8462026-03-31
Vanguard Portfolio Management LLC23,967,4002026-03-31
State Street Corporation19,324,4012026-03-31
State Farm Mutual Automobile Insurance Co15,892,9032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About Zoetis Inc.

Zoetis Inc. is led by CEO Kristin C. Peck, employs 13,800 people, headquartered in Parsippany, US, publicly traded since 2013.

Zoetis Inc. (ZTS) stock trades at $73.08 with a market capitalization of $30.64B. The stock is valued at a price-to-earnings (P/E) ratio of 11.69, price-to-book of 9.43, price-to-sales of 3.13. Over the past 52 weeks the stock has ranged between $69.03 and $148.79, and currently trades 50.9% below its 52-week high. It pays a dividend yielding 2.98%.

On profitability, Zoetis Inc. generates a return on equity (ROE) of 69.25% — well above the market average, a sign of a high-quality business, return on capital employed of 27.05%, an operating margin of 38.00%, a net profit margin of 27.49%.

In its most recent fiscal year, Zoetis Inc. reported annual revenue of $9.5B, net profit of $2.7B, revenue has compounded at 7.2% a year over the last five years, profit at 10.3% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 2.93 — a leveraged balance sheet worth monitoring, a current ratio of 3.03, total assets of $15.5B, $2.3B in cash and equivalents.

ZTS has a beta of 0.73 (less volatile than the overall market).

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides